Skip to textbook content
Doctor’s PassportTextbook
QuestionsFlashcardsBriefsDashboardAccount
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Acute antipsychotic treatment and physical monitoring

Psychiatry · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Severe reaction or uncontrolled psychotic danger

Hyperthermia with rigidity or autonomic instability, collapse, severe dystonia affecting breathing, marked QT-related symptoms, profound oversedation or immediate danger despite de-escalation requires emergency treatment rather than routine dose adjustment.

Action: Stop suspected offending treatment when clinically indicated, use ABCDE, glucose, temperature, ECG and targeted blood tests, and obtain emergency medical and senior psychiatric support. Manage behaviour with the least restrictive safe protocol, document total doses and reassess continuously.

Synopsis

Select and evaluate an oral antipsychotic collaboratively during acute psychosis, complete cardiovascular, metabolic, movement and reproductive safety assessment, recognise serious adverse reactions, and change one variable at a time using an explicit therapeutic trial.

  • Antipsychotic choice is a shared decision considering previous response, metabolic, movement, cardiovascular, hormonal and subjective effects rather than assuming one drug suits everyone.
  • Except for specific rapid-tranquillisation emergencies, offer an oral antipsychotic as an individual therapeutic trial and avoid routine loading doses or unplanned combined antipsychotics.
  • Record baseline weight, waist, pulse, blood pressure, fasting glucose or HbA1c, lipids, movement findings, nutrition, activity, prolactin and relevant ECG indications before treatment where feasible.
  • Specify target symptoms, starting dose, titration, expected review period, adherence support, adverse effects and the criteria for continuing, switching or stopping.
  • Discuss common subjective effects directly: sedation, emotional blunting, restlessness, sexual dysfunction, appetite change and stiffness often determine whether treatment is acceptable.
  • Monitor weight weekly for the first six weeks, again at twelve weeks and one year and then annually; measure waist annually, with glucose or HbA1c and lipids at twelve weeks, one year and annually thereafter.
  • Do not use a missed baseline measure to justify abandoning follow-up; document the acute reason, obtain it as soon as safe and assign ownership.
  • If response is poor, verify diagnosis, adherence, dose, duration, substances and tolerability before increasing, switching or declaring treatment resistance.

    • Key red flags

    Fever, generalised rigidity, altered consciousness, autonomic instability and rising creatine kinase after dopamine blockade suggests neuroleptic malignant syndrome.

    Syncope, palpitations, chest pain, severe hypotension or a markedly prolonged QT interval requires urgent cardiovascular assessment and medicine review.

    Painful neck, jaw, tongue or eye deviation soon after treatment may be acute dystonia; laryngeal involvement threatens the airway.

    New inner restlessness with pacing and inability to sit may be akathisia and can intensify distress, apparent agitation or suicidal thinking.

    Extreme thirst, polyuria, vomiting, abdominal pain, drowsiness or rapid breathing can indicate severe hyperglycaemia or diabetic ketoacidosis.

    Investigation priorities

    01
    Physical-health baselineFirst step

    Measure weight, waist, pulse, blood pressure, glucose or HbA1c, lipids, prolactin and movement status.

    Management branches

    Treatment selectionChoose one oral antipsychotic collaboratively

    Acute psychosis requires medication after safety and physical causes are assessed.

    1. Discuss previous response and metabolic, movement, cardiac, prolactin, sexual, sedative and subjective effects in relation to the person's priorities.
    2. Complete baseline measures, interaction and reproductive review and ECG when indicated, documenting any urgent measures that remain outstanding.
    3. Start one licensed oral medicine as a defined trial with target symptoms, titration, follow-up date and named monitoring responsibility.

    Key medicines

    Aripiprazole oralFor adult schizophrenia, start 10 mg or 15 mg by mouth once daily; the effective maintenance dose is usually 15 mg daily and the maximum is 30 mg daily.Monitor akathisia, activation, impulse-control symptoms, nausea and insomnia, review CYP2D6 and CYP3A4 interactions, and still complete weight, glucose, lipid, cardiovascular and movement surveillance.
    Risperidone oralFor adult schizophrenia, give 2 mg by mouth daily initially, which may be increased to 4 mg on the second day; most people benefit from 4 mg to 6 mg daily.Prolactin elevation, sexual or menstrual effects, extrapyramidal symptoms, orthostasis and metabolic change require discussion and monitoring; reduce and titrate cautiously in renal or hepatic impairment.
    Open full textbook →Answer 2 questions
    Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
    Sources

    Sources and review status

    National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

    • NICE CG178 psychosis and schizophrenia recommendationsShared antipsychotic choice, baseline assessment, trial principles and physical monitoring schedule.
    • Aripiprazole tablets summary of product characteristicsLicensed adult schizophrenia dosing, interactions, adverse effects and precautions.
    • Risperidone tablets summary of product characteristicsLicensed adult schizophrenia dosing, renal and hepatic adjustment and adverse effects.
    • NICE NG10 violence and aggression recommendationsSeparate emergency de-escalation, rapid tranquillisation and post-administration monitoring.

    Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

    Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom